Dalton Pharma Services has completed a $5 million expansion in sterile filling and API manufacturing at its cGMP facility in Toronto, Canada.

The project added three new sterile processing suites and an active pharmaceutical ingredient (API) manufacturing suite, and included the addition of a semi-automated powder filling line with significant scale-up of lyophilization capacity. Also included were increased analytical capabilities, increased chemistry capacity, and facility upgrades to meet increasingly stringent sterile manufacturing GMP API standards. Approximately 20 new skilled jobs have been added over the past year.

This expansion and improvements to Dalton’s sterile manufacturing facility were planned to meet growing clients’ requirements ranging from preclinical development and small/medium clinical trial batches to commercial production, for both API and sterile finished doses.

“Increasing sterile filling capability and capacity for both powders and liquids has been a key part of our plan for strategic growth,” said Peter Pekos, president and chief executive officer, Dalton. “Completion of this expansion is a major step designed to meet the increasing global demand for sterile filling development and production, and supports the integrated drug development and manufacturing we offer our clients.”